Known so far: no new shares from the prospectus covers read · shelf room about $2.9M · not yet read: warrants, converts, options, ATM.
Shelf room
Room todayabout $2.9M
One third of float$2.9M ($8.8M float, Dec 31, 2025)
Sold off it, 12 monthsnothing
How this is worked out
Shelf room about $2.9M on the S-3 of Mar 27, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $8.8M public float stated as of Dec 31, 2025, $2.9M, nothing sold off it in the last 12 months. Sources: S-3 Mar 27, 2026, effective Apr 14, 2026 · public float, as of Dec 31, 2025.
What could become new Moleculin Biotech (MBRX) shares, from its 10-Q, 10-K, S-1 or 424B filings.
Read so far: the cover share count (19.5M shares, +1508% from 1.2M on Aug 5, 2025, adjusted for the 1-for-25 reverse split by Mar 11, 2026). Not read yet: warrants, convertible notes, options and RSUs and an ATM program.Read them on EDGAR: the latest 10-Q · S-1 registration filings.
Registrations and share actions on EDGAR (51 filings)
Registration statements, prospectuses, effectiveness notices, information statements and share sales, newest first. Showing the newest 15 of 51. Each links to the filing on EDGAR.
S-8Registration of shares for employee stock plans
424B5Prospectus for shares being soldSize not read yet
8-K + 424B5Financing: agreement (8-K) with a 424B5 prospectus filed the same daySize not read yet
S-1Registration statement; new shares or resale not read yet
8-K + 424B5Financing: agreement and unregistered share sale (8-K) with a 424B5 prospectus filed a day apartSize not read yet
S-8Registration of shares for employee stock plans
Shares outstanding
19.5M
Nov 2024 to Aug 2026: from 120K to 19.5M. Adjusted for the 1-for-25 reverse split by Mar 11, 2026: each earlier count is divided by the ratio of every split after it.
From the share count on the cover of each 10-Q and 10-K, dated as each cover states.
Follow Moleculin Biotech
New shelves, offerings, 10-Qs and 10-Ks from MBRX, explained in plain English when they reach EDGAR.
